Concurrent initiation of tirzepatide and biologics improves patient-reported outcomes in obese psoriatic arthritis: a propensity score-matched study
Vincenzo Venerito, Giuseppe Lopalco, Cristiana Colaprico, Daniele Catamerò, Fabio Cacciapaglia, Florenzo Iannone · 2026
Read Concurrent initiation of tirzepatide and biologics improves patient-reported outcomes in obese psoriatic arthritis: a propensity score-matched study by Vincenzo Venerito, Giuseppe Lopalco, Cristiana Colaprico, Daniele Catamerò, Fabio Cacciapaglia, Florenzo Iannone (2026) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/PMC13423080.txt.
Description
Venerito and colleagues pair a weight-loss drug with biologic therapy in this 2026 matched study of obese patients with psoriatic arthritis, a joint-and-skin disease where obesity blunts biologic response. Thirty-one patients starting tirzepatide, a dual-action metabolic drug, alongside a biologic were matched to 62 similar patients starting biologics alone, and outcomes were compared at six months.
The combination group lost body mass index while controls gained slightly, a gap of minus 2.9 versus plus 0.4 points on the index, and their inflammation marker CRP ended significantly lower. Patient-acceptable symptom state on a disease-impact questionnaire was reached by 48 percent of the tirzepatide group against 21 percent of controls, an odds ratio of 3.44 in the matched analysis, and near-clear skin was also more common. Physician-scored joint targets did not separate significantly, a subthreshold pattern the authors read as real but partial benefit.
Catalog record
| CREATOR | Vincenzo Venerito, Giuseppe Lopalco, Cristiana Colaprico, Daniele Catamerò, Fabio Cacciapaglia, Florenzo Iannone |
|---|---|
| YEAR | 2026 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 25 KB |
| LICENSE | https://creativecommons.org/licenses/by/4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |